← SynDRA
FEBUXOSTAT
SynDRA canonical compound SYN0022558 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | XDH |
|---|
| Mechanism of action | Xanthine oxidase inhibitor |
|---|
| Indication | hyperuricemia |
|---|
| Disease area | nephrology |
|---|
All known targets
- XDH
- ABCG2
- BLVRB
- KCNH2
- Xdh
Mechanisms of action (all sources)
- Xanthine oxidase inhibitor
- XDH INHIBITOR
- Xanthine dehydrogenase inhibitor
Drug classes
- Xanthine Oxidase Inhibitors
- Antirheumatic Agents
- Gout Suppressants
- Xanthine Oxidase Inhibitor
ATC classes
- M04A · ANTIGOUT PREPARATIONS
Cross-references
Synonyms
- februxostat
- feburic
- uloric
- adenuric
- NSC-758874
- TMX-67
- Adenuric
- Febuxostat krka
- Febuxostat mylan
- Febuxostat viatris (previously febuxostat mylan)
- Uloric
- TEI
- Febuxostat [USAN]
- S1547
- Tei-6720
- Uloric (TN)
- Febuxostat (JAN/USAN/INN)
- TMX-67, Adenuric, Uloric, Febuxostat
- 111GE013
- 2-(3-CYANO-4-ISOBUTOXY-PHENYL)-4-METHYL-5-THIAZOLE-CARBOXYLIC ACID
- 2-(3-Cyano-4-(2-methylpropoxy)phenyl)-4-methylthiazole-5-carboxylic acid;2-(3-Cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylic acid
- 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid
- TMX 67
- NSC 758874
- Zurig
- Febuxostatum
- DTXCID1028576
- CHEBI:31596
- TEI6720
- RefChem:57913
- Febuxostat tablets 40 mg
- Febuxostat tablets 80 mg
- M04AA03
- Feburic
- MFCD00871598
- Febuxostat (Uloric)
- NCGC00182059-02
- SMR002529566
Reported adverse events
- Arthralgia
- Rash
- Death
- Infestation
- Nausea
- Guillain-Barre syndrome
- Stevens-Johnson syndrome
Look up FEBUXOSTAT in the interactive SynDRA portal →